SELE and acute myeloid leukemia: Given that a phase 1/2 clinical trial has demonstrated the addition of the E-selectin antagonist uproleselan (GMI-1271) to chemotherapy is well tolerated and associated with high remission rates and improved survival in acute myeloid leukemia (40), incorporating E-selectin antagonists into chemotherapy might offer a promising therapeutic option for NPC.